Skip to main content

Table 1 Study characteristics

From: Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis

study

No. of patients

Gender M/F

Age (< 70/≥70)

Smoking status (C or F /N)

Treatment

Detecting Items for Drug-Resistance Mechanism

Uramoto H et al. [10]

11

3/8

7/4

2/9

gefitinib

T790 M, KRAS,PTEN MET amp, HGF status

Kuiper JL et al. [11]

66

14/52

NA

30/33a

erlotinib gefitinib

T790 M, SCLC, KRAS

Sun JM et al. [12]

70

18/52

NA

14/56

erlotinib gefitinib

T790 M

Li W et al. [13]

54

29/25

49/5

7/47

erlotinib gefitinib Icotinib

T790 M

Sequist LV et al. [14]

37

15/22

31/6

NA

erlotinib gefitinib

T790 M, MET amp, SCLC, PIK3CA, EMT

Kosaka T et al. [15]

14

4/10

NA

6/8

Gefitinib

T790 M, KRAS

Oxnard GR et al. [16]

93

33/60

NA

32/61

erlotinib gefitinib

T790 M, MET amp, HER2

Hata A et al. [17]

78

24/54

51/27

24/54

erlotinib gefitinib

T790 M

Chen HJ et al. [18]

29

18/11

27/2

6/23

erlotinib gefitinib

T790 M, MET amp

Ji W et al. [19]

26

10/16

21/5

NA

gefitinib

T790 M, MET amp, AXL, EMT, CD56

  1. aUncertain for the 3 cases; C or F /N = current or former /never smoker